For personal use only

Market Announcement

13 February 2025

Recce Pharmaceuticals Ltd (ASX: RCE) – Trading Halt

Description

The securities of Recce Pharmaceuticals Ltd ('RCE') will be placed in trading halt at the request of RCE, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 17 February 2025 or when the announcement is released to the market.

Issued by

ASX Compliance

For personal use only

Recce Pharmaceuticals
recce.com.au
ACN 124 849 065

13 February 2025

Barbara Lim
Adviser, Listing Compliance (Perth)
Level 40 Central Park
152 - 158 St Georges Terrace
Perth WA 6000

By email: tradinghaltsperth@asx.com.au

Dear Barbara,

Recce Pharmaceuticals Ltd (ASX:RCE) – Trading halt request

Pursuant to ASX Listing Rule 17.1, Recce Pharmaceuticals Ltd (**Company**) requests a trading halt of the Company's securities pending the release of a material announcement relating to Phase II Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Clinical Trial Data (the '**Results**').

The Company requests that the trading halt be effective immediately and remain in place until the earlier of the commencement of normal trading on Monday, 17 February 2025 or the release of an announcement by the Company in relation to the Results.

The Company is not aware of any reason why the trading halt should not be granted nor any other information necessary to inform the market about the trading halt.

This announcement has been approved for release by Recce Pharmaceuticals Board.

For further information, please contact:

Maggie Niewidok
Company Secretary
company.secretary@recce.com.au